PROCEPT BioRobotics Securities Fraud Class Action
Analysis based on 267 articles · First reported Jul 24, 2026 · Last updated Aug 21, 2026
The disclosure of inventory issues and revenue miss caused PROCEPT's stock to drop sharply, eroding investor confidence. The securities class action adds legal and financial overhang, potentially leading to significant settlement costs and further reputational damage.
PROCEPT BioRobotics Corporation, a medical technology company, faces a securities fraud class action lawsuit alleging it used an undisclosed bulk discount program to artificially inflate U.S. handpiece sales and revenues by pulling forward demand. The company disclosed on February 25, 2026 that handpiece sales had exceeded procedures every quarter since Q1 2023, resulting in over 10,000 excess units of field inventory. This led to a nearly 30% sequential decline in Q4 handpiece sales and a miss of annual revenue guidance. The stock fell over 18% in two days following the disclosure, and by February 25, 2026 had declined over 48% from August 2025. Multiple law firms, including Kahn Swick & Foti, Hagens Berman, Pomerantz, Robbins Geller, Kaplan Fox, Rosen Law Firm, Glancy Prongay, The Gross Law Firm, DJS Law Group, and Law Offices of Howard G. Smith, have filed or announced class actions. The lead plaintiff deadline is September 22, 2026, and the case is pending in the United States — United States District Court for the Northern District of California.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard